Table 1.
Characteristics of patients with acute brucellosis (AB).
| Patient# | Sex | Age(years) | Symptoms/Findings | Route of transmission | Wright SAT | Bloodculture | Antibiotictreatment |
|---|---|---|---|---|---|---|---|
| AB1 | F | 40 | Fatigue, malaise myalgias, arthralgias | Consumption | 1/640 | N/A | Rifampicin Doxycycline |
| AB2 | F | 53 | Fever, sweating, arthralgias, peripheral arthritis | Consumption | 1/320 | Negative | Rifampicin Doxycycline Amikacin |
| AB3 | M | 31 | Fever, sweating, fatigue | Consumption/contact | 1/320 | Negative | Rifampicin Doxycycline Amikacin |
| AB4 | M | 36 | Fever, sweating, malaise, fatigue | Consumption | 1/5120 | Negative | Rifampicin Doxycycline Amikacin |
| AB5 | M | 55 | Fever, sweating, lumbar spondylitis | Contact | 1/160 | Brucella spp | Rifampicin Doxycycline Amikacin |
| AB6 | M | 39 | Fever, myalgia | Contact | 1/320 | Brucella spp | Rifampicin Doxycycline Amikacin |
| AB7 | M | 64 | Sweating, fatigue, low back pain | Consumption | 1/320 | Brucella spp | Rifampicin Doxycycline Amikacin |
| AB8 | F | 45 | Fatigue, lumbar spondylitis | Consumption | 1/640 | N/A | Rifampicin Doxycycline Amikacin |
| AB9 | M | 18 | Fever, sweating, malaise, fatigue myalgias, arthralgias | Consumption/contact | 1/160 | Brucella spp | Rifampicin Doxycycline Amikacin |
| AB10 | M | 52 | Fatigue, myalgias, arthralgias, peripheral arthritis | Contact/REV1 vaccine | 1/160 | Negative | Rifampicin Doxycycline |
| Age (years, mean ± SD) | 43.3 ± 13.4 | ||||||
F, female; M, male; N/A, not available; SAT, serum agglutination test; SD, standard deviation.
Duration of antibiotic treatment was 8-12 weeks for rifampicin (600 mg/daily) and doxycycline (200 mg/daily), and 2-3 weeks for Amikacin (1 gr/daily).